Thomas Ginn
Internal Medicine · Bryan, TXNPI 1770506511
Payments from drug & device makers
Across 463 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$660
- AstraZeneca$619
- Pfizer$588
- Astellas Pharma US Inc$393
- Boehringer Ingelheim$392
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,08497%
- Education$2243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 104 | $1,414 |
| AbbVie(2 entities) | 53 | $660 |
| AstraZeneca | 27 | $619 |
| Pfizer | 49 | $588 |
| Astellas Pharma US Inc | 16 | $393 |
| Boehringer Ingelheim | 27 | $392 |
| Amarin Pharma, Inc. | 19 | $340 |
| Lilly USA, LLC | 24 | $335 |
| Amgen | 16 | $253 |
| Sanofi-aventis U.S. LLC | 17 | $247 |
| Bayer | 8 | $219 |
| Kowa Pharmaceuticals America, Inc. | 13 | $201 |
| Esperion Therapeutics, Inc. | 7 | $200 |
| Johnson & Johnson | 11 | $186 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $151 |
| Biohaven Pharmaceuticals, Inc. | 1 | $124 |
| Merck | 8 | $121 |
| GSK | 9 | $119 |
| Sunovion Pharmaceuticals Inc. | 6 | $116 |
| E.r. Squibb & Sons, L.L.C. | 5 | $87 |
| Hikma Pharmaceuticals USA | 5 | $76 |
| Genentech USA, Inc. | 4 | $70 |
| Antares Pharma, Inc. | 2 | $31 |
| Dexcom, Inc. | 2 | $31 |
| Seqirus USA Inc | 2 | $30 |
| Novartis | 2 | $29 |
| Eisai Inc. | 2 | $28 |
| Itamar Medical Inc | 1 | $28 |
| Medtronic(2 entities) | 2 | $27 |
| Philips North America LLC | 2 | $26 |
| Neuronetics, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$124
- FARXIGA$109
- NEXLIZET$104
- NEXLETOL$104
How this compares
$7,308 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Bryan
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.